Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response.

Geerts H, Spiros A, Roberts P, Twyman R, Alphs L, Grace AA.

PLoS One. 2012;7(12):e49732. doi: 10.1371/journal.pone.0049732. Epub 2012 Dec 14.

PMID:
23251349
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
[PubMed - indexed for MEDLINE]
3.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
[PubMed - indexed for MEDLINE]
4.

The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action.

Offord SJ, Wong DF, Nyberg S.

J Clin Pharmacol. 1999 Aug;Suppl:17S-24S. Review.

PMID:
10434243
[PubMed - indexed for MEDLINE]
5.

Olanzapine for schizophrenia.

Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S.

Cochrane Database Syst Rev. 2003;(1):CD001359. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD001359.

PMID:
12535408
[PubMed - indexed for MEDLINE]
6.

Olanzapine for schizophrenia.

Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S.

Cochrane Database Syst Rev. 2000;(2):CD001359. Review. Update in: Cochrane Database Syst Rev. 2003;(1):CD001359.

PMID:
10796640
[PubMed - indexed for MEDLINE]
7.

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA.

Mol Psychiatry. 2012 Dec;17(12):1206-27. doi: 10.1038/mp.2012.47. Epub 2012 May 15. Review.

PMID:
22584864
[PubMed - indexed for MEDLINE]
8.

[Cognition, schizophrenia and the effect of antipsychotics].

Stip E.

Encephale. 2006 May-Jun;32(3 Pt 1):341-50. Review. French.

PMID:
16840928
[PubMed - indexed for MEDLINE]
9.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
[PubMed - indexed for MEDLINE]
10.

Imaging as tool to investigate psychoses and antipsychotics.

Booij J, van Amelsvoort T.

Handb Exp Pharmacol. 2012;(212):299-337. doi: 10.1007/978-3-642-25761-2_12. Review.

PMID:
23129337
[PubMed - indexed for MEDLINE]
11.

New atypical antipsychotics for schizophrenia: iloperidone.

Caccia S, Pasina L, Nobili A.

Drug Des Devel Ther. 2010 Feb 18;4:33-48. Review.

PMID:
20368905
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2009 Aug;63(8):1237-48. doi: 10.1111/j.1742-1241.2009.02142.x. Review.

PMID:
19624791
[PubMed - indexed for MEDLINE]
13.

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2009 Dec;63(12):1762-84. doi: 10.1111/j.1742-1241.2009.02228.x. Epub 2009 Oct 14. Review.

PMID:
19840150
[PubMed - indexed for MEDLINE]
14.

Olanzapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review.

PMID:
20238348
[PubMed - indexed for MEDLINE]
15.

Risperidone: review of its pharmacology and therapeutic use in schizophrenia.

Gupta S, Black DW, Smith DA.

Ann Clin Psychiatry. 1994 Sep;6(3):173-80. Review.

PMID:
7533585
[PubMed - indexed for MEDLINE]
16.

Iloperidone for the treatment of schizophrenia.

Marino J, Caballero J.

Ann Pharmacother. 2010 May;44(5):863-70. doi: 10.1345/aph.1M603. Epub 2010 Apr 13. Review.

PMID:
20388862
[PubMed - indexed for MEDLINE]
17.

Antipsychotic occupancy of dopamine receptors in schizophrenia.

Nord M, Farde L.

CNS Neurosci Ther. 2011 Apr;17(2):97-103. doi: 10.1111/j.1755-5949.2010.00222.x. Epub 2010 Dec 8. Review.

PMID:
21143431
[PubMed - indexed for MEDLINE]
18.

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Bishara D, Taylor D.

Drugs. 2008;68(16):2269-92. doi: 10.2165/0003495-200868160-00002. Review.

PMID:
18973393
[PubMed - indexed for MEDLINE]
19.

The evolution of the serotonin-dopamine antagonist concept.

Huttunen M.

J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):4S-10S. Review.

PMID:
7730499
[PubMed - indexed for MEDLINE]
20.

Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.

Grant S, Fitton A.

Drugs. 1994 Aug;48(2):253-73. Review.

PMID:
7527327
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk